Structure Therapeutics Inc (GPCR)

$37.84 -0.48 (-1.25%)
Market Cap 2.71B
Revenue (ttm) 0.00
Net Income (ttm) -141.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 556,800
Avg Vol 977,980
Day's Range N/A - N/A
Shares Out 70.84M
Stochastic %K 6%
Beta -1.31
Analysts Strong Sell
Price Target $108.31

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 1978
Address:
601 Gateway Boulevard, Suite 900, South San Francisco, United States
forprofit12
forprofit12 May. 13 at 11:56 AM
$GPCR I bought this last time at 22 and one of my worst decision was to sell it in 22 after holding it for a few months and missing the run up to 90. Not making the same mistake again. If it rerates, it rerates big.
0 · Reply
POWELL_
POWELL_ May. 13 at 12:50 AM
$GPCR NVO didnt do well with glp1 this isnt it sir
0 · Reply
JUST_FACTSSS
JUST_FACTSSS May. 12 at 6:45 PM
$GPCR resting on trendline MUST STAY ABOVE IT
0 · Reply
Wallst45
Wallst45 May. 11 at 8:10 PM
$GPCR yes gone case
1 · Reply
AR15lph
AR15lph May. 11 at 6:54 PM
$GPCR Happy I sold covered calls for May 15th that will expire worthless, looking forward to June 5-8th conference.
0 · Reply
kellyc09
kellyc09 May. 11 at 4:32 PM
$GPCR Boy everyone talks about this company but the stock is down everyday and now down almost 50% the last three months. Not sure how much I could take waiting for good news or a buy out .
0 · Reply
biolover
biolover May. 11 at 2:48 PM
$VKTX looking at $KLRA and $GPCR volumes last few days. All day trading and price manipulation. Not serious new investors. A lot of VK is market makers as well
0 · Reply
JuggernautRaider
JuggernautRaider May. 10 at 7:44 PM
$ALT $GPCR $VKTX quick I need a GLP-1 after enjoying some Mother’s Day Steak Frites. Which clinical stage should I choose? 😋
1 · Reply
Merlintrader
Merlintrader May. 9 at 2:59 PM
$ALT Viking Therapeutics $VKTX, Structure Therapeutics $GPCR and Altimmune : The Next Obesity Drug Race https://www.merlintrader.com/viking-structure-alt-the-next-race/
3 · Reply
TheinvestmetABCD
TheinvestmetABCD May. 8 at 11:15 PM
$GPCR accumulating more and more in the $30 range. We might go one last time sub $34, before blowing up. Buyers are waiting for Roche´s data for their GLP1 drug. If strucutre is still ahead, we will see the buyout at a $8-10 billion valuation in my opinion
1 · Reply
Latest News on GPCR
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

May 7, 2026, 4:05 PM EDT - 5 days ago

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

Apr 27, 2026, 4:05 PM EDT - 15 days ago

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

Canaccord starts Structure Therapeutics on oral weight loss pipeline

2026-04-27T12:58:41.000Z - 15 days ago

Canaccord starts Structure Therapeutics on oral weight loss pipeline

Structure Therapeutics initiated with a Buy at Canaccord

2026-04-27T10:00:27.000Z - 16 days ago

Structure Therapeutics initiated with a Buy at Canaccord

Structure Therapeutics appoints Matthew Lang as COO

2026-04-14T20:17:51.000Z - 4 weeks ago

Structure Therapeutics appoints Matthew Lang as COO

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Apr 14, 2026, 4:05 PM EDT - 4 weeks ago

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright

2026-03-16T15:55:34.000Z - 2 months ago

Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright

Structure’s GLP-1 pill could put company on M&A radar, Barron’s says

2026-03-16T15:10:26.000Z - 2 months ago

Structure’s GLP-1 pill could put company on M&A radar, Barron’s says

LLY NVO

Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?

Mar 16, 2026, 10:46 AM EDT - 2 months ago

Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?

Structure Therapeutics Transcript: Study result

Mar 16, 2026, 8:30 AM EDT - 2 months ago

Structure Therapeutics Transcript: Study result

Structure Therapeutics: Aleniglipron achieved meaningful weight loss in study

2026-03-16T11:22:17.000Z - 2 months ago

Structure Therapeutics: Aleniglipron achieved meaningful weight loss in study

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Mar 16, 2026, 7:00 AM EDT - 2 months ago

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright

2026-03-02T11:26:56.000Z - 2 months ago

Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright

Structure Therapeutics price target lowered to $113 from $120 at Citizens

2026-02-27T10:55:51.000Z - 2 months ago

Structure Therapeutics price target lowered to $113 from $120 at Citizens

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Feb 26, 2026, 4:02 PM EST - 2 months ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 3 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN LLY NVO PFE VKTX

Structure Therapeutics emerges as top M&A target for big pharma, Axios says

2026-01-30T15:51:54.000Z - 3 months ago

Structure Therapeutics emerges as top M&A target for big pharma, Axios says

Structure Therapeutics price target raised to $105 from $65 at JPMorgan

2026-01-22T11:51:35.000Z - 3 months ago

Structure Therapeutics price target raised to $105 from $65 at JPMorgan

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Jan 21, 2026, 10:05 AM EST - 3 months ago

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Structure Therapeutics price target raised to $140 from $90 at Guggenheim

2026-01-20T12:26:42.000Z - 4 months ago

Structure Therapeutics price target raised to $140 from $90 at Guggenheim

Structure Therapeutics moved to Buy rating at Goldman Sachs

2026-01-19T22:30:27.000Z - 4 months ago

Structure Therapeutics moved to Buy rating at Goldman Sachs

LLY

Structure CEO Ray Stevens talks its obesity drug portfolio

Jan 15, 2026, 6:21 PM EST - 4 months ago

Structure CEO Ray Stevens talks its obesity drug portfolio

Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher

2026-01-14T18:05:20.000Z - 4 months ago

Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher

LLY NVO PFE TERN VKTX

Structure Therapeutics rises 14.1%

2026-01-13T17:05:46.000Z - 4 months ago

Structure Therapeutics rises 14.1%

Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright

2025-12-19T13:45:27.000Z - 5 months ago

Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright

Structure Therapeutics announces initiation of Phase 1 study of ACCG-2671

2025-12-17T13:35:49.000Z - 5 months ago

Structure Therapeutics announces initiation of Phase 1 study of ACCG-2671

Structure Therapeutics price target raised to $125 from $120 at Morgan Stanley

2025-12-12T13:18:17.000Z - 5 months ago

Structure Therapeutics price target raised to $125 from $120 at Morgan Stanley

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Dec 11, 2025, 4:01 PM EST - 5 months ago

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Dec 9, 2025, 11:15 PM EST - 5 months ago

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Dec 8, 2025, 4:01 PM EST - 5 months ago

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Dec 8, 2025, 11:20 AM EST - 5 months ago

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Structure Therapeutics Transcript: Study Update

Dec 8, 2025, 8:30 AM EST - 5 months ago

Structure Therapeutics Transcript: Study Update

Structure's experimental pill shows 11% weight loss in study, shares up

Dec 8, 2025, 8:14 AM EST - 5 months ago

Structure's experimental pill shows 11% weight loss in study, shares up

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Dec 8, 2025, 8:00 AM EST - 5 months ago

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Dec 7, 2025, 6:20 PM EST - 5 months ago

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Final Trade: UBER, CRWV, GPCR, DIS

Nov 10, 2025, 6:21 PM EST - 6 months ago

Final Trade: UBER, CRWV, GPCR, DIS

CRWV UBER DIS

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 6, 2025, 4:01 PM EST - 6 months ago

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Fast Money: DAL, ROKU, AAPL, GPCR

Nov 5, 2025, 6:21 PM EST - 6 months ago

Fast Money: DAL, ROKU, AAPL, GPCR

AAPL ROKU DAL

Structure Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 10:45 AM EDT - 8 months ago

Structure Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Structure Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 3:55 PM EDT - 8 months ago

Structure Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 4:01 PM EDT - 9 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 11 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Jun 20, 2025, 7:30 PM EDT - 11 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Structure Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 10:40 AM EDT - 11 months ago

Structure Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 1 year ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:26 PM EDT - 1 year ago

Structure Therapeutics CEO on latest GLP-1 developments

Final Trade: PYPL, UBER, NKE, GPCR

Mar 24, 2025, 6:23 PM EDT - 1 year ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Structure Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 1:00 PM EDT - 1 year ago

Structure Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Structure Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 10:30 AM EST - 1 year ago

Structure Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 30, 2025, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Structure Therapeutics Transcript: Study Update

Dec 17, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 17, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure CEO on the competitive landscape for oral GLP-1 drugs

Dec 5, 2024, 6:17 PM EST - 1 year ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Structure Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 3:00 AM EST - 1 year ago

Structure Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Transcript: Study Update

Nov 13, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Nov 13, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Structure Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2024, 9:10 AM EDT - 1 year ago

Structure Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Structure Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 5, 2024, 10:00 AM EDT - 1 year ago

Structure Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Structure Therapeutics CEO on GLP drugs

Jun 11, 2024, 6:37 PM EDT - 2 years ago

Structure Therapeutics CEO on GLP drugs

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 7, 2024, 4:05 PM EDT - 2 years ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 5, 2024, 7:53 PM EDT - 2 years ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 6:27 PM EDT - 2 years ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 4:09 PM EDT - 2 years ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 2:38 PM EDT - 2 years ago

Structure Therapeutics reports promising weight-loss drug data

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 8:42 AM EDT - 2 years ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Structure Therapeutics Transcript: Study Update

Jun 3, 2024, 8:30 AM EDT - 2 years ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Jun 3, 2024, 7:30 AM EDT - 2 years ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

May 7, 2024, 11:33 AM EDT - 2 years ago

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

AMGN LLY NVO ALT AZN VKTX

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

Apr 16, 2024, 7:09 PM EDT - 2 years ago

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

AMGN AZN LLY NVO PFE SNY VKTX

Structure Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Structure Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

Mar 9, 2024, 2:30 AM EST - 2 years ago

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

NVO PFE VKTX

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Mar 8, 2024, 4:05 PM EST - 2 years ago

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Mar 8, 2024, 8:30 AM EST - 2 years ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

Jan 17, 2024, 3:40 PM EST - 2 years ago

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

VKTX TERN

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

Dec 20, 2023, 11:17 AM EST - 2 years ago

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

LLY NVO ALT AMGN VKTX

Structure Therapeutics reports promising results for weight-loss pill

Dec 18, 2023, 11:56 AM EST - 2 years ago

Structure Therapeutics reports promising results for weight-loss pill

forprofit12
forprofit12 May. 13 at 11:56 AM
$GPCR I bought this last time at 22 and one of my worst decision was to sell it in 22 after holding it for a few months and missing the run up to 90. Not making the same mistake again. If it rerates, it rerates big.
0 · Reply
POWELL_
POWELL_ May. 13 at 12:50 AM
$GPCR NVO didnt do well with glp1 this isnt it sir
0 · Reply
JUST_FACTSSS
JUST_FACTSSS May. 12 at 6:45 PM
$GPCR resting on trendline MUST STAY ABOVE IT
0 · Reply
Wallst45
Wallst45 May. 11 at 8:10 PM
$GPCR yes gone case
1 · Reply
AR15lph
AR15lph May. 11 at 6:54 PM
$GPCR Happy I sold covered calls for May 15th that will expire worthless, looking forward to June 5-8th conference.
0 · Reply
kellyc09
kellyc09 May. 11 at 4:32 PM
$GPCR Boy everyone talks about this company but the stock is down everyday and now down almost 50% the last three months. Not sure how much I could take waiting for good news or a buy out .
0 · Reply
biolover
biolover May. 11 at 2:48 PM
$VKTX looking at $KLRA and $GPCR volumes last few days. All day trading and price manipulation. Not serious new investors. A lot of VK is market makers as well
0 · Reply
JuggernautRaider
JuggernautRaider May. 10 at 7:44 PM
$ALT $GPCR $VKTX quick I need a GLP-1 after enjoying some Mother’s Day Steak Frites. Which clinical stage should I choose? 😋
1 · Reply
Merlintrader
Merlintrader May. 9 at 2:59 PM
$ALT Viking Therapeutics $VKTX, Structure Therapeutics $GPCR and Altimmune : The Next Obesity Drug Race https://www.merlintrader.com/viking-structure-alt-the-next-race/
3 · Reply
TheinvestmetABCD
TheinvestmetABCD May. 8 at 11:15 PM
$GPCR accumulating more and more in the $30 range. We might go one last time sub $34, before blowing up. Buyers are waiting for Roche´s data for their GLP1 drug. If strucutre is still ahead, we will see the buyout at a $8-10 billion valuation in my opinion
1 · Reply
GhostTrader11
GhostTrader11 May. 8 at 4:54 PM
$GPCR getting close to that 35.81 gap fill. Waiting....
0 · Reply
forprofit12
forprofit12 May. 8 at 4:26 PM
$GPCR not a story these are facts. If a buy out happens or not depends on how negotiations go but where there is smoke there is fire.
1 · Reply
parrotineum
parrotineum May. 8 at 4:06 PM
$GPCR heard this story at SP of $94.
0 · Reply
Twitgb
Twitgb May. 8 at 3:10 PM
$VKTX who can tell @Kylenorth why he made a bad choice with $GPCR in comparison with $VKTX?
0 · Reply
forprofit12
forprofit12 May. 8 at 1:17 PM
$GPCR 3 out of 4 companies sold by CEO
0 · Reply
forprofit12
forprofit12 May. 8 at 1:14 PM
$GPCR buyout in the next 6 months. Both CEO and COO specialists building and selling companies
0 · Reply
blocktrade
blocktrade May. 7 at 11:37 PM
$GPCR nice chart
1 · Reply
bigmoneygrip9
bigmoneygrip9 May. 7 at 11:17 PM
$GPCR was there an offering today regarding this amended sales agreement with leerick partners and cantor Fitzgerald? Increase atm shares offering by 150 million to aggregate 400$ million? Is that how I read it? Is this an offering or private placement ?
2 · Reply
Fundmentalstrader
Fundmentalstrader May. 7 at 10:21 PM
$GPCR ER was great everything i was looking for
0 · Reply
AR15lph
AR15lph May. 7 at 9:10 PM
$GPCR reported earnings today ah , inline.
0 · Reply
blocktrade
blocktrade May. 7 at 8:57 PM
$GPCR it’s almost time for some clown on fast money to mention gpcr
0 · Reply
Twitgb
Twitgb May. 7 at 8:43 PM
$GPCR kyle, are you still here?
1 · Reply